[Dynamics of Biochemical Markers of Endothelial Dysfunction in Patients With Arterial Hypertension]

V I Podzolkov1, A I Tarzimanova1

  • 1Sechenov First Moscow State Medical University, Moscow, Russia.

Kardiologiia
|March 15, 2017
PubMed

Insights

Arterial hypertension (AH) and atrial fibrillation (AF) increase cardiovascular risk. This study links endothelial dysfunction markers, like von Willebrand factor, to AF in hypertensive patients, aiding risk prediction.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Hypertension Research

Background:

  • Arterial hypertension (AH) is a primary cause of atrial fibrillation (AF).
  • AF in hypertensive patients significantly heightens cardiovascular complication risks.
  • Endothelial dysfunction (ED) may predict thromboembolic complications in AH patients with AF.

Purpose of the Study:

  • To investigate biochemical markers of ED in patients with AH and different forms of AF.
  • To assess the prognostic value of ED markers for thromboembolic risk stratification.

Main Methods:

  • Studied collagen binding activity of von Willebrand factor (vWF).
  • Measured plasma endothelin concentrations.
  • Correlated ED markers with AH severity and AF characteristics (paroxysmal frequency).

Main Results:

  • Collagen binding activity of vWF was significantly higher in permanent AF patients versus controls, independent of AH severity.
  • A moderate correlation was found between annual AF paroxysm frequency and vWF activity in persistent AF.
  • Endothelin levels increased with AH severity in both AF and non-AF patients, irrespective of AF form.

Conclusions:

  • Elevated vWF activity is associated with permanent AF in hypertensive individuals.
  • vWF activity may correlate with AF burden in persistent AF.
  • Endothelin levels reflect AH severity but not AF type.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
668
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
689
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.3K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.6K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
546
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
667